Published in Eur J Clin Microbiol Infect Dis on May 04, 2012
An outbreak of extremely drug-resistant Pseudomonas aeruginosa in a tertiary care pediatric hospital in Italy. BMC Infect Dis (2014) 0.94
Prospective observational study of prior rectal colonization status as a predictor for subsequent development of Pseudomonas aeruginosa clinical infections. Antimicrob Agents Chemother (2015) 0.85
New Insight on Epidemiology and Management of Bacterial Bloodstream Infection in Patients with Hematological Malignancies. Mediterr J Hematol Infect Dis (2015) 0.85
Clinical and treatment-related risk factors for nosocomial colonisation with extensively drug-resistant Pseudomonas aeruginosa in a haematological patient population: a matched case control study. BMC Infect Dis (2014) 0.75
The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa. Hum Vaccin Immunother (2016) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect (2011) 17.47
Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med (2002) 8.67
Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N Engl J Med (2000) 5.08
A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis (2007) 3.39
Efflux-mediated resistance to fluoroquinolones in gram-negative bacteria. Antimicrob Agents Chemother (2000) 3.22
Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother (1999) 3.16
Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother (2006) 3.09
Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med (1999) 3.08
Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother (2005) 2.08
Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis (2008) 1.91
Acquisition of multidrug-resistant Pseudomonas aeruginosa in patients in intensive care units: role of antibiotics with antipseudomonal activity. Clin Infect Dis (2004) 1.89
Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa. Clin Infect Dis (1999) 1.83
Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis (1997) 1.82
Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother (2007) 1.58
Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect (2004) 1.33
Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis (2001) 1.28
Influence of previous exposure to antibiotic therapy on the susceptibility pattern of Pseudomonas aeruginosa bacteremic isolates. Clin Infect Dis (2001) 1.22
Pseudomonas aeruginosa in adults with chronic obstructive pulmonary disease. Curr Opin Pulm Med (2009) 1.10
A large sustained endemic outbreak of multiresistant Pseudomonas aeruginosa: a new epidemiological scenario for nosocomial acquisition. BMC Infect Dis (2011) 1.07
Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection. J Hosp Infect (2004) 1.06
Nosocomial outbreak of a non-cefepime-susceptible ceftazidime-susceptible Pseudomonas aeruginosa strain overexpressing MexXY-OprM and producing an integron-borne PSE-1 betta-lactamase. J Clin Microbiol (2009) 1.04
Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol Infect (2011) 0.97
Stimulation of innate immunity by susceptible and multidrug-resistant Pseudomonas aeruginosa: an in vitro and in vivo study. Clin Exp Immunol (2004) 0.97
Effect of multidrug resistance-conferring mutations on the fitness and virulence of Pseudomonas aeruginosa. J Antimicrob Chemother (2011) 0.97
Previous ciprofloxacin exposure is associated with resistance to beta-lactam antibiotics in subsequent Pseudomonas aeruginosa bacteremic isolates. Am J Infect Control (2009) 0.89
Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care (2000) 0.83
Mosquito cell cultures and specific monoclonal antibodies in surveillance for dengue viruses. Am J Trop Med Hyg (1984) 5.42
OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother (2000) 4.08
Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis (2006) 3.34
Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol (2000) 3.23
Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol (2001) 3.06
Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. N Engl J Med (1987) 2.78
Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1998) 2.40
Vancomycin in surgical infections due to methicillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin. Lancet (1999) 2.30
Characteristics and antibiotic therapy of adult meningitis due to penicillin-resistant pneumococci. Am J Med (1988) 2.24
Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother (1991) 2.13
A controlled trial of home-based acute psychiatric services. I: Clinical and social outcome. Br J Psychiatry (1993) 2.10
Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Spanish hospitals. Antimicrob Agents Chemother (2007) 2.04
Characteristics of prosthetic joint infections due to Enterococcus sp. and predictors of failure: a multi-national study. Clin Microbiol Infect (2014) 2.02
Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother (1998) 2.00
Effects of antibiotics on protected specimen brush sampling in ventilator-associated pneumonia. Eur Respir J (2002) 2.00
[Tetany in a patient with the acquired immunodeficiency syndrome treated with foscarnet]. Med Clin (Barc) (1992) 1.99
Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol (2001) 1.98
Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. J Oral Maxillofac Surg (1996) 1.89
Risk factors for nosocomial bacteremia due to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis (1994) 1.85
Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother (1995) 1.78
Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as risk factor for colonization and infection. Clin Infect Dis (2000) 1.74
Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis (1996) 1.68
Characteristics of and risk factors for relapse of brucellosis in humans. Clin Infect Dis (1995) 1.67
Streptococcal meningitis in adult patients: current epidemiology and clinical spectrum. Clin Infect Dis (1999) 1.66
Comparative trial of rifampin-doxycycline versus tetracycline-streptomycin in the therapy of human brucellosis. Antimicrob Agents Chemother (1985) 1.63
Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol (2008) 1.63
Evaluation of the Wider system, a new computer-assisted image-processing device for bacterial identification and susceptibility testing. J Clin Microbiol (2000) 1.62
The outcome after treatment of venous thromboembolism is different in surgical and acutely ill medical patients. Findings from the RIETE registry. J Thromb Haemost (2004) 1.62
Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med (1996) 1.61
Risk factors for nosocomial Legionella pneumophila pneumonia. Am J Respir Crit Care Med (1994) 1.61
Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clin Microbiol Infect (2014) 1.61
[Proteinuria and chronic renal failure in the coast of El Salvador: detection with low cost methods and associated factors]. Nefrologia (2005) 1.59
Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect (1997) 1.58
D-Dimer is an early diagnostic marker of coronary ischemia in patients with chest pain. Am Heart J (2000) 1.57
Molecular characterization of FOX-4, a new AmpC-type plasmid-mediated beta-lactamase from an Escherichia coli strain isolated in Spain. Antimicrob Agents Chemother (2000) 1.56
Doppler echocardiographic assessment of progression of aortic regurgitation. Am J Cardiol (1997) 1.52
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother (1996) 1.51
p53 and proliferating cell nuclear antigen expression in JC virus-infected cells of progressive multifocal leukoencephalopathy. Hum Pathol (1994) 1.51
Evolution of leukotriene B4, peptide leukotrienes, and interleukin-8 plasma concentrations in patients at risk of acute respiratory distress syndrome and with acute respiratory distress syndrome: mortality prognostic study. Crit Care Med (2000) 1.50
Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant (2003) 1.50
Infected hip hemiarthroplasties and total hip arthroplasties: Differential findings and prognosis. J Infect (2013) 1.49
Use of 'original antigenic sin' theory to determine the serotypes of previous dengue infections. Trans R Soc Trop Med Hyg (1993) 1.47
Community-acquired bacteremic Pseudomonas cepacia pneumonia in an immunocompetent host. Clin Infect Dis (1992) 1.47
Prophylactic platelet transfusion threshold during therapy for adult acute myeloid leukemia: 10,000/microL versus 20,000/microL. Haematologica (1998) 1.47
Changes in reticulocyte fractions during peripheral stem cell harvesting: role in monitoring stem cell collection. Bone Marrow Transplant (1996) 1.41
Prognostic value of the ankle-brachial index in elderly patients with a stable chronic cardiovascular event. J Thromb Haemost (2010) 1.39
Clinical validity of the 'mini-mental state' for Spanish speaking communities. Neuropsychologia (2001) 1.39
Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother (2009) 1.38
Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother (2010) 1.38
Complement is not activated in AB0-haemolytic disease of the newborn: two exceptions. Vox Sang (1991) 1.38
Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis (1999) 1.36
Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost (1997) 1.36
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) (2013) 1.33
Specific antibodies detected during relapse of human brucellosis. J Infect Dis (1988) 1.33
Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting. Clin Microbiol Infect (2005) 1.32
In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis. J Antimicrob Chemother (1986) 1.32
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect (2005) 1.27
Gram-negative bacillary cellulitis in patients with hepatic cirrhosis. Eur J Clin Microbiol Infect Dis (1994) 1.27
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis (1995) 1.27
Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother (2002) 1.26
Comparative sensitivity of three mosquito cell lines for isolation of dengue viruses. Bull World Health Organ (1985) 1.26
Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect (2008) 1.23
Delayed haemolytic transfusion reaction due to anti-M antibody. Br J Haematol (1998) 1.23
Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother (2006) 1.22
Molecular epidemiology of methicillin-resistant Staphylococcus aureus in Majorcan hospitals: high prevalence of the epidemic clone EMRSA-15. Clin Microbiol Infect (2007) 1.21
Recording and analyzing high-density event-related potentials with infants. Using the Geodesic sensor net. Dev Neuropsychol (2001) 1.20
Pneumococcal peritonitis in adult patients: report of 64 cases with special reference to emergence of antibiotic resistance. Arch Intern Med (2001) 1.19
Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect (2012) 1.16
Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect (2006) 1.16
Nosocomial spread of Pseudomonas aeruginosa producing the metallo-beta-lactamase VIM-2 in a Spanish hospital: clinical and epidemiological implications. Clin Microbiol Infect (2007) 1.16
Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis. Antimicrob Agents Chemother (1986) 1.16
Electronic laboratory system reduces errors in National Tuberculosis Program: a cluster randomized controlled trial. Int J Tuberc Lung Dis (2010) 1.14
Comparative trial of co-trimoxazole versus tetracycline-streptomycin in treating human brucellosis. J Infect Dis (1985) 1.14
Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis (2012) 1.14
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients. Antimicrob Agents Chemother (2007) 1.14